Digital cellular telephones and ICDs

neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Cardiol 2000; 86: 417–21. [3] Briguori C, Betocchi S, Manganelli F et al. Determinants and clinical significance of natriuretic peptides in hypertrophic cardiomyopathy. Eur Heart J 2001; 22: 1328–36. [4] Criley JM, Siegel RJ. Has ‘obstruction’ hindered our understanding of hypertrophic cardiomyopathy? Circulation 1985; 72: 1148–54. [5] Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336: 775–85. [6] Nishigaki K, Tomita M, Kagawa K et al. Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1996; 28: 1234–42. [7] Wijbenga AA, Balk AH, Jonkman FA, Boomsma F, Simoons ML, Man in’t Veld AJ. Relation of atrial natriuretic peptide to left ventricular systolic and diastolic function in heart failure. Eur J Heart Fail 1999; 1: 51–8. [8] Yamamoto K, Burnett JC, Redfield MM. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol 1997; 273: H2406–H2414. [9] Clarkson PB, Wheeldon NM, MacFadyen RJ, Pringle SD, MacDonald TM. Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure. Circulation 1996; 93: 2037–42. [10] Paulus WJ, Shah AM. NO and cardiac diastolic function. Cardiovasc Res 1999; 43: 595–606. [11] Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000; 343: 246–53.